300347 泰格医药
2026/09 - 九个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-1.3404.2661.9439.97210.643
总资产报酬率 ROA (%)-0.9663.1141.3897.0897.840
投入资产回报率 ROIC (%)-1.1463.6611.6278.2779.110

边际利润分析
销售毛利率 (%)27.34927.41533.95438.57739.637
营业利润率 (%)0.21014.77310.06233.68036.446
息税前利润/营业总收入 (%)1.30616.14410.63932.23534.257
净利润/营业总收入 (%)-2.14211.7826.78229.11632.062

收益指标分析
经营活动净收益/利润总额(%)5,806.24151.849149.45573.53474.609
价值变动净收益/利润总额(%)-5,733.54747.455-50.42427.76524.701
营业外收支净额/利润总额(%)-23.096-0.6180.0060.0640.115

偿债能力分析
流动比率 (X)2.5432.1791.7202.7412.978
速动比率 (X)2.5202.1641.7122.7352.972
资产负债率 (%)16.88214.46616.06717.61117.363
带息债务/全部投入资本 (%)14.2099.93113.09414.35313.711
股东权益/带息债务 (%)588.505879.094644.373578.707604.915
股东权益/负债合计 (%)415.655510.912448.724402.258410.935
利息保障倍数 (X)1.15111.04218.455-21.973-15.350

营运能力分析
应收账款周转天数 (天)65.95672.85371.43355.78646.665
存货周转天数 (天)3.3532.6662.2851.8101.191